Post archive for ‘Company Reports’
Cytokinetics: Phase 3 Trial for Tirasemtiv About to Begin with Topline Results Possible in 2H, 2016; Successful Outcome Could Make the Stock a Homerun (CYTK, $6.35, Buy, For Paid Subscribers)
Introduction Management has recently provided details of the upcoming phase 3 trial of tirasemtiv in the treatment of ALS; this trial is named VITALITY- ALS which is short for Ventilator Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS This trial will begin any day now and could report […]
Discovery Laboratories: An Analysis of Phase 2a Results for Aerosurf and What to do with the Stock (DSCO, $0.81, for paid subscribers)
Glossary of Important Definitions For those of you who are not familiar with terms used in neonatology, I am starting this report with some definitions used in this report to explain the outcome of the recent phase 2a trial of Aerosurf. Surfactant Surfactant coats the alveoli (the air sacs in the lungs where oxygen enters […]
Antares: One of My Top Stock Picks for 2015 and 2016 (ATRS, Buy, $2.40, For Paid Subscribers)
Introduction to Report One of my assets is also one of my biggest drawbacks. When I am writing on a Company I start out thinking that I have a good understanding of the Company, but inevitably as I dig deeper, I find out that the more information I gather the more questions that arise in […]
Observations from ASCO on Immuno-oncology with a Focus on Northwest Biotherapeutics’ (NWBO, Buy, $9.43) DC-Vax-Direct© and the Checkpoint Inhibitors of Bristol-Myers Squibb and Merck
Key Investment Points Stemming from ASCO I have been going over data presented at ASCO on immune-oncology products and have been listening carefully to the presentations by Northwest Biotherapeutics and other companies active in this space, particularly Bristol-Myers Squibb and Merck. Let me summarize some of my key takeaways which will be addressed in more […]
Comments on Alimera (ALIM, $4.46, Neutral) and pSivida (PSDV, $3.97, Neutral)
SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]
Cytokinetics: Takeaways from Recent R&D Day and Reiteration of Buy (CYTK, $6.14, Buy)
Investment Overview I find the recent stock weakness in Cytokinetics perplexing. The Company has a market value of about $300 million which seems extremely low relative to other biotechnology companies. Generally companies with meaningful drugs in phase 3 development have market capitalizations of $500 million or more. Cytokinetics has two very meaningful drugs: tirasemtiv will […]
Agenus: Its R&D Day Presentation Puts a Focus on the Great Promise of Cancer Vaccines and Checkpoint Modulators (AGEN, Buy, $6.73)
Overview of Report I found the Agenus R&D day to be extremely interesting as it showcased the impressive immunotherapy technology base of Agenus. Presentations by management and key opinion leaders went into great detail on the Company’s core Prophage cancer vaccine and checkpoint modulator technologies. I have included bullet points on remarks that most interested […]
Cytokinetics: Update and Reiteration of My Buy Recommendation (CYTK, $5.54, Buy)
Investment Thesis in Brief By the end of 2015, Cytokinetics (CYTK) will have tirasemtiv in a phase 3 trial in ALS and might also have omecamtiv in a phase 3 trial in heart failure. There is no financing overhang as the Company has $118 million of cash which can last for over 20 months. This […]
Northwest Biotherapeutics: FDA Panel Recommendation to Approve Amgen’s Cancer Vaccine is Hugely Significant In Regard to Possible Approval of DCVax-L and DCVax Direct. (NWBO, $7.86, Buy)
Overview An FDA advisory panel on April 30 recommended by a vote of 22 to 1 that Amgen’s cancer vaccine talimogene laherparepvec be approved for the treatment of later stages of inoperable metastatic melanoma. The final decision will be made by the FDA, but it would be very surprising for the FDA to go against […]
CAR-T Companies-Kite (KITE, $55.09) and Juno (JUNO, $47.30): Is The Bloom Coming Off The Rose? Are Investor Expectations Unrealistic?
Introduction to This Thought Piece Emerging biotechnology stocks obviously are very hard to value on an absolute basis because they usually have no or minimal sales and huge operating losses. Many Wall Street analysts arrive at price targets by making long term sales and earnings projections; risk adjusting the estimates through predicting probability of successful […]